Back to News
Market Impact: 0.25
Is AbbVie a Buy After Its Latest Earnings Report?
Source: fool.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
AbbVie's adjusted EPS nearly doubled, although much of the increase reflects a large research-deal charge in the prior year; underlying growth was closer to 17%. Skyrizi and Rinvoq now represent nearly half of revenue, supporting growth while increasing product concentration risk.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
ABBV0.20
More News
- AbbVie: 3 Key Takeaways for Long-Term Investors
- Stocks started the week with promise but ended in despair. Our take on the big reversal
- Intel stock plunges 29%. Analysts urge caution on buying the dip
- How Ambani’s Jio became India’s second-largest company
- AWS grows 39% and Amazon will spend even more on AI in 2027
- The $13 billion startup racing to close America’s hypersonic gap